Details of the Drug

General Information of Drug (ID: DM0CEY3)

Drug Name

Lefaxin

Synonyms

PYRIDOSTIGMINE BROMIDE; 101-26-8; Mestinon; Kalimin; Regonal; Kalymin; Mestinon bromide; 3-((Dimethylcarbamoyl)oxy)-1-methylpyridin-1-ium bromide; 3-(Dimethylcarbamoyloxy)-1-methylpyridinium Bromide; Pyridostigmine (bromide); UNII-KVI301NA53; Piridostigmina bromuro [DCIT]; CCRIS 6798; HSDB 3924; 3-[(dimethylcarbamoyl)oxy]-1-methylpyridin-1-ium bromide; Pyridostigmini bromidum [INN-Latin]; EINECS 202-929-9; Ro 1-5130; Bromure de pyridostigmine [INN-French]; Pyridostigmini bromidum; Bromuro de piridostigmina [INN-Spanish

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

261.12

Topological Polar Surface Area

Not Available

Rotatable Bond Count

2

Hydrogen Bond Donor Count

0

Hydrogen Bond Acceptor Count

3

Chemical Identifiers

Formula: C9H13BrN2O2
IUPAC Name: (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate;bromide
Canonical SMILES: C[N+]1=CC=CC(=C1)OC(=O)N(C)C.[Br-]
InChI: InChI=1S/C9H13N2O2.BrH/c1-10(2)9(12)13-8-5-4-6-11(3)7-8;/h4-7H,1-3H3;1H/q+1;/p-1
InChIKey: VNYBTNPBYXSMOO-UHFFFAOYSA-M

Cross-matching ID

PubChem CID: 7550
ChEBI ID: CHEBI:8666
CAS Number: 101-26-8
TTD ID: D09KKU

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor Xa (F10)	TTCIHJA	FA10_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Discovery agent

ICD Disease Classification

N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Coagulation factor Xa (F10)	DTT	F10	4.84E-02	-0.28	-0.9

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
2	Pfizer. Product Development Pipeline. March 31 2009.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
5	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
6	Company report (Portola)
7	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
8	Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
9	Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
10	Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
11	Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.